NOVEL ERGOLINE ANALOGS

• US 20110152280A1
• Filed: 12/23/2010
• Published: 06/23/2011
• Est. Priority Date: 12/23/2009
• Status: Active Grant

• Current Assignee: MAP Pharmaceuticals, Inc. (Abbvie Incorporated)
• Original Assignee: MAP Pharmaceuticals, Inc. (Abbvie Incorporated)
• Inventors: COOK, ROBERT O., Kosarev, Sergey Alexandrovich, Xie, Dejian, Armer, Thomas A.
• Granted Patent: US 8,710,092 B2
• Time in Patent Office: Days
• US Class Current: 514/250
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: C07D 457/04 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
• CPC Class Codes: C07D 519/02 Ergot alkaloids of the cyclic peptide type

Abstract

Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT_1D and or 5-HT_1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT_2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.

Claims

1. A compound of Formula (I):

2. A compound of Formula (II):

3. A method of treating or preventing migraine in a patient comprising administering to a patient in need thereof a compound of Formula (I):

4. A method of treating or preventing ALS, Parkinson'"'"'s disease, extra-pyramidal disorders, depression, nausea, restless legs syndrome, insomnia, aggression, Huntington'"'"'s disease, dystonia, parsomnia and hyperlactinemia in a patient comprising administering to a patient in need thereof a compound of Formula (I):

5. A method of administering a compound of Formula (I):

6. The method of claim 5, wherein the dose range is between about 0.1 mg and about 100 mg and about 0.2 mg and about 100 mg

7. A method of treating or preventing migraine, ALS, Parkinson'"'"'s disease, extra-pyramidal disorders, depression, nausea, restless legs syndrome, insomnia, aggression, Huntington'"'"'s disease, dystonia, parsomnia and hyperlactinemia in a patient comprising administering to a patient in need thereof a compound of Formula (II):